Immunovant, Inc. (IMVT): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMVT Stock Price Chart Interactive Chart >
IMVT Price/Volume Stats
|Current price||$18.41||52-week high||$20.24|
|Prev. close||$17.75||52-week low||$3.14|
|Day high||$18.52||Avg. volume||1,299,373|
|50-day MA||$16.59||Dividend yield||N/A|
|200-day MA||$8.72||Market Cap||2.38B|
Immunovant, Inc. (IMVT) Company Bio
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Most Popular Stories View All
IMVT Latest News Stream
|Loading, please wait...|
IMVT Latest Social Stream
View Full IMVT Social Stream
Latest IMVT News From Around the Web
Below are the latest news stories about IMMUNOVANT INC that investors may wish to consider to help them evaluate IMVT as an investment opportunity.
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expectedPhase 3 clinical trial of batoclimab in myasthenia gravis (MG) is ongoing Cash balance of approximately $433 million as of December 31, 2022 NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a cl
In the latter half of 2022, the S&P dropped 7%.
The share price of Immunovant Inc. (NASDAQ:IMVT) fell to $18.06 per share on Tuesday from $18.60. While Immunovant Inc. has underperformed by -2.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IMVT rose by 147.40%, with highs and lows ranging from $20.24 to $3.14, whereas the […]
Immunovant is developing a similar drug to argenx, but at 10% of argenx’s valuation. Read more to see the growth catalysts, risks and why I consider it a buy now.
Immunovant Inc. (IMVT)’s stock is trading at $19.06 at the moment marking a rise of 3.08% from the last session close. As of this writing, shares are priced at -2.76% less than their 52-week high of $19.60, and 506.04% over their 52-week low of $3.14. Based on the past 30-day period, the stock price is […]
IMVT Price Returns